An End-to-end Approach to Precision Medicine
FoundationOne CDx was recently approved to identify mutations that lead to MET exon 14 skipping in advanced non-small cell lung cancer (NSCLC) and match patients with a new targeted therapy, which was approved in parallel. Learn more about how this approval demonstrates the power of cancer precision medicine in action and the role that comprehensive genomic profiling plays.
From the Foundation Forward Blog
November 16, 2020
October 15, 2020
September 14, 2020
August 27, 2020
August 05, 2020